Rectify Pharmaceuticals, founded with a mission to develop innovative disease-modifying therapeutics, focuses on creating Positive Functional Modulators (PFMs) to treat serious ABC transporter-mediated diseases. The company's vision is to rectify dysfunctional protein transport mechanisms, thereby restoring hope and improving the lives of patients suffering from these conditions. Their core product line includes small molecule therapeutics designed to restore and enhance the function of ABC transporters, addressing the root cause of these diseases.

Notable figures affiliated with Rectify Pharmaceuticals include leading scientists and industry experts in biotechnology. The company has garnered significant interest and investment from prominent venture capital firms specializing in life sciences. Key achievements include advancing their therapeutic candidates through critical stages of preclinical development, demonstrating promising efficacy in early studies. Rectify Pharmaceuticals has made a substantial impact by pioneering treatments for previously untapped therapeutic areas, offering new hope to patients with limited options.